PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.

doi:10.1158/1078-0432.CCR-20-1731

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2020

Guarneri Valentina, Dieci Maria Vittoria, Bisagni Giancarlo, Brandes Alba A, Frassoldati Antonio, Cavanna Luigi, Musolino Antonino, Giotta Francesco, Rimanti Anita, Garrone Ornella, Bertone Elena, Cagossi Katia, Nanni Oriana, Piacentini Federico, Orvieto Enrico, Griguolo Gaia, Curtarello Matteo, Urso Loredana, Paré Laia, Chic Nuria, D'Amico Roberto, Prat Aleix, Conte Pierfranco

Abstract excerpt

PURPOSE: We explored the prognostic effect of PIK3CA mutation in HER2+ patients enrolled in the ShortHER trial. PATIENTS AND METHODS: The ShortHER trial randomized 1,253 patients with HER2+ breast cancer to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. PIK3CA hotspot mutations in exon 9 and 20 were analyzed by pyrosequencing. Expression of 60 genes, including PAM50 genes was measured using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8 Antigens

Share to Class I Phosphatidylinositol 3-Kinases

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 32843527
DOI: 10.1158/1078-0432.CCR-20-1731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.PMID 32843527Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Semantic proximity Read ↗

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.Semantic proximity Read ↗

Cross-Platform Reproducible Modeling of Breast Cancer Prognosis Using the Core-PAM50 Gene SignatureSemantic proximity Read ↗

Associations of TILs and genomic alterations in HER2+ early breast cancer.Semantic proximity Read ↗

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patientsSemantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer PatientsSemantic proximity Read ↗

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.Semantic proximity Read ↗

Survival Outcomes by TP53 Mutation Status in Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.